Quality of life in young patients with chronic myelocytic leukaemia during intensive treatment including interferon

Leukemia Research

Volumn 21, Issue 8, 1997, Pages 775-783

  Stalfelt, Ann Marie ^a   Zettervall, Olle ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ABMT; CML; Intensive treatment; Interferon; Quality of life

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; HYDROXYUREA; INTERFERON; MITOXANTRONE; RECOMBINANT ALPHA2B INTERFERON;

ABSENTEEISM; ADULT; ALOPECIA; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; PATIENT ATTITUDE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SWEDEN;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; FEMALE; HUMANS; INTERFERONS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; QUALITY OF LIFE; SICK LEAVE; TRANSPLANTATION, AUTOLOGOUS;

EID: 0030724856     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(97)00026-X     Document Type: Article

References (30)

1. Spencer, A., O'Brien, S. G. and Goldman, J. M., Options for therapy in chronic myeloid leukemia. British Journal of Haematology, 1995, 91, 2.
2. Alimena, G., Morra, E. and Lazzarino, M. et al., Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood, 1988, 72, 642.
3. Cunningham, I., Gee, T. and Dowling, M. et al., Results of treatment of Ph' + chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol). Blood, 1979, 53, 375.
4. Reiffers, J., Goldman, J., Meloni, G., Cahn, J. Y. and Gratwohl, A., On behalf of the chronic leukemia working party of the EBMT. Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European group for bone marrow transplantation. Bone Marrow Transplantation, 1994, 14, 407.
5. Simonsson, B., Öberg, G. and Killander, A. et al., For the Swedish CML-group. Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia. Bone Marrow Transplantation, suppl. 3, 1994, 14, 55.
6. Talpaz, M., Kantarjian, H. M., McCredie, K., Trujillo, J. M., Keating, M. J. and Gutterman, J. U., Hematologica! remission and cytogenetic improvement induced by recombinant human Interferon alpha in chronic myelogenous leukemia. New England Journal of Medicine, 1986, 314, 1065.
7. Italian cooperative group on chronic myeloid leukemia, Interferon alpha-2a as compared with conventional chemotherapy for treatment of chronic myeloid leukemia. New England Journal of Medicine, 1994, 330, 820.
8. Kantarjian, H. M., Smith, T. L., O'Brian, S., Beran, M., Pierce, S. and Talpaz, M., Prolonged survival in chronic myelogenous leukemia after cytogenetic response to Interferon a therapy. Annals of Internal Medicine, 1995, 122, 254.
9. Hehlmann, R., Heimpel, H. and Hasford, J. et al, Randomized comparison of Interferon alpha with busulfan and hydroxurea in chronic myelogenous leukemia. Blood, 1994, 84, 4064.
10. Quality of life in clinical trials. Editorial. Lancet, 1995, 346, 1.
11. Cella, D. F. and Tulsky, D. S., Measuring quality of life today: methodological aspects. Oncology, 1990, 4, 29.
12. Carlens, E., Dahlström, G. and Nou, E., Comparative measurements of quality of survival of lung cancer patients after diagnosis. Scandinavian Journal of Respiratory Diseases, 1970, 51, 268.
13. Stalfelt, A. M. and Wadman, B., Assessing quality of life in leukaemia: presentation of an instrument for assessing quality of life in patients with blood malignancies. Quality Assurance in Health Care, 1993, 5, 201.
14. Stalfelt, A. M., Quality of Life in patients with acute myeloid leukaemia. Leukaemia Research, 1994, 18, 257.
15. O'Brien, P. C. and Shampo, M. A., Statistical considerations for performing multiple tests in a single experiment. 2. Comparisons among several therapies. Mayo Clinic-Proceedings, 1988, 63, 816.
16. Hjorth, M., Holmberg, E., Rödjer, S., Taube, A. and Westin, J., Physicians' attitudes towards clinical trials and their relationship to patient accrual in a nordic multicenter study on myeloma. Controlled Clinical Trials, 1997, 17, 372.
17. André, M. Facing death. A study of doctors strategies with cancer patients. University of Umea, Thesis 1994.
18. Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, S., Fleishman, S. B., de Haes, J. C. J. M., Kaasa, S., Klee, M., Osoba, D., Razavi, D., Rofe, P. B., Schraub, S., Sneeuw, K., Sullivan, M. and Takeda, F., The European Organiza-tion for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 1993, 85, 365.
19. Wisløff, F., Hjorth, M., Kaasa, S. and Westin, J., Effect of interfereon on the health-related quality of life in multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-predni-sone + a-interferon. British Journal of Haematology, 1996, 94, 324.
20. Moinpour, C. M., Measuring quality of life: an emerging science. Seminars in Oncology, Suppl. 10, 1994, 21, 48.
21. De Boer, J. B., van Dam, F. S., Sprangers, M. A., Frissen, P. H. and Lange, J. M., Longitudinal study on the quality of life of symptomatic HIV-infected patients in a trial of zidovudine versus zidovudine and interferon alpha. AIDS, 1993, 7, 947.
22. Hill, M., Norman, A., Cunningham, D., Findlay, M., Watson, M., Nicolson, V., Webb, A., Middleton, G., Ahmed, F. and Hickish, T. et al, Impact of protraced venous infusion with or without interferon alpha-2b on tumor response, survival and quality of life in advanced colorectal cancer. Journal of Clinical Oncology, 1995, 13, 2317.
23. Orion, A. M., Gaion, R. M., Cordelia, L., Bano, F., Cannada, R. A., Innamorati, G. and Berti, T., Interferon-alpha. Results of a pharmaco-epidemiologic study. Clinical Ter., 1994, 144, 201.
24. Finelli, H., Gugliotta, L., Garnen, B., Vianelli, N., Visani, G. and Tura, S., Relief of intractable pruritus in polycytemia vera with recombinant interferon alpha. American Journal of Hematology, 1993, 43, 316.
25. Martinez, O. and Rubio-Borja, M. E., All-transretinoic acid plus 2 A interferon for the treatment of accelerated phase of chronic myeloid leukemia. Blood, 10(Suppl. 1), 1995, 86, 775.
26. Stalfelt, A. M., Quality of life during induction treatment of acute myelocytic leukaemia. A comparison of three intensive chemotherapy regimens using a new quality of life assessment instrument. Acta Oncologica, 1994, 33, 477.
27. Altmaier, E. M., Gingrich, R. D. and Fyfe, M. A., Two-year adjustment of bone marrow survivors. Bone Marrow Transplant, 1991,7,311.
28. Andrykowski, M. A., Altmaier, E. M., Barnett, R. L., Otis, M. L., Gingrich, R. and Hensle-Downey, P. J., The quality of life in adult survivors of allogenic bone marrow transplantation. Transplantation, 1990, 50, 399.
29. Nelson, J. C., Tierny, D. K., Bloom, J. R., Long, G. D., Barr, T. A. and Stallbaum, B. A., Dynamic assessment of quality of life after autologous bone marrow trans-plantation. Blood, 1992, 80, 825.
30. Zittoun, R., Suciu, S., Golbu, G., Watson, M., Muss, P. and Mandelli, F. etal., Comparison of quality of life of patients with acute myelogenous leukemias in long term first complete remission after bone marrow transplantation-allogenic or autologous-or intensive chemotherapy consolidation: EORTC-Ginema AML 8A study. Psychological Oncology, 1996, 5, 210.